一种新型无创通气辅助设备，休息-活动周期-正气道压，在健康成年人运动人卡塔尔世界杯8强波胆分析群中的效用和可接受性:队列研究%A Reeve,Julie %A Mooney,Sarah %A Jepsen,Nicola %A White,David %+奥克兰理工大学临床科学学院，物理治疗系，90 Akoranga Drive, Auckland, 0627，新西兰，64 9219999 ext 7951, nicola.jepsen@aut.ac.nz %K无创伤通风%K运动%K可行性%K人类%K COPD %K理疗%K肺康复%K康复%D 2022 %7 1.8.2022 %9原始论文%J JMIR Rehabil Assist Technol %G英文%X背景:无创通气已被证明有利于中度至重度慢性阻塞性肺疾病急性加重期患者。研究已经开始调查无创通气在肺康复中的有效性，以改善慢性阻塞性肺疾病患者的预后;然而，这些设备缺乏便携性和加湿性，这意味着它们的使用受到限制，特别是在进行日常生活活动时。一种新的原型设备racerpap(休息-活动周期-气道正压)，通过鼻界面提供电池操作的气道正压，同时调节鼻气道分配偏差，消除了补充湿化的需要。该装置可提高慢性阻塞性肺病患者参与肺部康复和日常生活活动的能力。目的:评估在正常健康人群中使用RACer-PAP原位运动的可行性以及该装置在运动中的可接受性。方法:共邀请15名健康成年人参加2次运动，每次间隔1周。疗程持续约1小时，包括2次基线6分钟步行距离评估，一次在原地使用和一次不使用RACer-PAP。 Vital signs and spirometry results were monitored throughout, and spirometry was performed pre- and posttesting with RACer-PAP. Subjective questionnaires ascertained participant feedback on exercising with the device in situ. Results: Of the 15 initial participants, 14 (93%) completed both sessions. There were no adverse events associated with exercising with the device in situ. There were no differences in vital signs or 6-minute walk distance whether exercising with or without the device in situ. There were small increases in maximum dyspnea score (on the Borg scale) when exercising with the device in situ (median score 2.0, IQR 0.5-3.0, vs 3.0, IQR 2.0-3.25). There were small increases in forced vital capacity following exercise with the RACer-PAP. None of the participants reported symptoms associated with airway drying. Participant feedback provided recommendations for modifications for the next iteration of the device prior to piloting the device with people with chronic obstructive pulmonary disease. Conclusions: This study has shown RACer-PAP to be safe and feasible to use during exercise and has provided feedback for modifications to the device to improve its use during exercise. We now propose to consider the application of the device in a small pilot feasibility study to assess the safety, feasibility, and utility of the device in a population of people with moderate to severe chronic obstructive pulmonary disease. Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12619000478112; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375477 %M 35916705 %R 10.2196/35494 %U https://rehab.www.mybigtv.com/2022/3/e35494 %U https://doi.org/10.2196/35494 %U http://www.ncbi.nlm.nih.gov/pubmed/35916705